Actionable news
0
All posts from Actionable news
Actionable news in SPPI: Spectrum Pharmaceuticals, Inc.,

AAAP to be acquired by Novartis; ​Voyager VYGR takes back full rights for Parkinson’s disease program

Price and Volume Movers

Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced that its partner Sanofi Genzyme has opted not to take on development and commercial rights of VY-AADC program for advanced Parkinson’s disease. According to Voyager, Sanofi’s decision was due to the inclusion of rights only outside of the US. As a result, Voyager gains full worldwide development and commercial rights to VY-AADC, which will enter a pivotal Phase 2-3 program later this year. Shares are trading down 12% to $20.00 after hours.

Johnson & Johnson (NYSE:JNJ) announced the FDA approved the 10 mg once-daily dose of XARELTO (rivaroxaban) for reducing the continued risk for recurrent venous thromboembolism (VTE) after completing at least six months of initial anticoagulation therapy.

Advanced Accelerator Applications S.A. (NASDAQ: AAAP) shares closed up 10% to $18.50 following news Novartis intends to acquire the company for $41 per ordinary share and $82 per ADS, for a total of $3.9b.

Aviragen Therapeutics, Inc. (NASDAQ:AVIR) announced a merger with privately held Vaxart, Inc, with a new ticker or VXRT.

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) rose sharply to close up 21% to $23.61. The company received an Outperform rating from Evercore ISI Group and a $85 price target.

Other major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume INCLUDING sub-$1 stocks.

ADVANCERS:

CARDIOME PHARMA CORP (NASDAQ:CRME): $1.52; +16%.

Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE): $1.22; +14%.

Mustang Bio Inc (NASDAQ:MBIO): $9.99; +13%.

Global Blood Therapeutics Inc (NASDAQ:GBT): $38.65; +13%.

Cerecor Inc (NASDAQ:CERC): $1.10; +12%.

DECLINERS:

Pluristem Therapeutics Inc. (NASDAQ:PSTI): $1.68; -15%.

Achieve Life Sciences Inc (NASDAQ:ACHV): $1.81; -13%.

Proteon Therapeutics Inc (NASDAQ:PRTO): $1.75; -13%.

Fibrocell Science Inc (NASDAQ:FCSC): $2.15; -11%.

Pain Therapeutics, Inc. (NASDAQ:PTIE): $3.47; -10%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst

CANF
CF101
Rheumatoid arthritis

Phase 3 Phase 3 commencement of enrollment announced October 30, 2017.

GWPH
Epidiolex
Lennox-Gastaut syndrome (LGS)

NDA Filing First Phase 3 trial data released June 2016. Data from second Phase 3 trial also met endpoint - September 2016. NDA submission announced October 30, 2017.

GWPH
Epidiolex
Dravet Syndrome

NDA Filing Top line Phase 3 data released March 2016 met primary endpoint. NDA submission announced October 30, 2017.

JNJ
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)

Approved Approval announced October 30, 2017.

SPPI
Poziotinib
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2

Phase 2 Phase 2 initiation announced October 30, 2017.

More